Introduction A few studies have evaluated the efficacy and safety of noninsulated radiofrequency microneedling (RFMN) to treat periorbital wrinkles in Asian patients. Recently, wound healing accelerators, polynucleotides (PNs), have received attention in wound management. However, their efficacy and safety have not been fully elucidated following RFNM. This study aimed to evaluate the efficacy and safety of noninsulated RFMN for periorbital wrinkles and the synergistic effect of PNs after RFMN. Methods Thirty subjects with Fitzpatrick skin types III to V and facial wrinkles (Fitzpatrick grades I and II) were enrolled. All volunteers were treated over the entire face with noninsulated RFMN for three sessions at 2-week intervals. The left and right sides of each patient’s face were randomly assigned to receive PNs (treatment group) or normal saline solution (control group). The indentation and maximum depth of wrinkles were objectively measured using Antera 3D. Subjective self-evaluations were obtained at baseline, 2 weeks after the third treatment, and at 1, 2, 3, and 6 months after the final treatment. In addition, pain scores, immediate reactions, and other adverse effects were evaluated. Results Twenty-nine subjects completed the treatment protocol. Most presented with grade II wrinkling (69%). At 2-month follow-up, Antera 3D image analysis revealed faster improvement for the treatment group. At 6-month follow-up, the majority of subjects reported an improvement of 25–75% in their periorbital wrinkles. The average pain score was 2.2 out of 10. No serious adverse events (infection, pigmentary alteration, persistent erythema, or scarring) were observed. Conclusions Noninsulated RFMN is safe and effective for treating periorbital wrinkles and can be used as a modality for transdermal drug delivery. Topical polynucleotides as an adjunctive treatment provide additional benefits for periorbital wrinkle treatment. Trial Registration Number TCTR20201105007.

Introduction: Monopolar radiofrequency (MRF) is a valuable modality for tightening and contouring mild-to-moderate facial skin laxity. Few studies have evaluated new-generation MRF devices for lower facial laxity in Asians. This study aims to evaluate the efficacy and safety of MRF for treating lower facial laxity in Asians. Methods: This prospective cohort study enrolled 30 volunteers with Fitzpatrick Skin Types III-V and mild-to-moderate skin laxity. Subjects received a single MRF treatment. Self-assessments and adverse events were recorded. Two blinded dermatologists graded improvements (6-point scale) after treatment and 1, 3, and 6 months later. Results: All subjects completed the study. Treatment energy levels ranged from 2 to 4. The average number of shots was 412 ± 49, delivered in 3-4 passes with 15-30% overlap. All patients reported improvement in lower facial laxity immediately after treatment. Most patients had mild-to-moderate improvement over the 6-month follow-up. Continuous improvement was observed at the 1-, 3-, and 6-month follow-ups (P \ 0.01). Significant improvement was seen at the 6-month followup compared with the 1-month follow-up (P \ 0.01). Subjects tolerated the procedure well: the average pain score was 3.13 out of 10, and no serious adverse events were observed. Conclusions: The new-generation MRF device we tested was effective and safe for mild-tomoderate lower facial laxity in Asian skin. The latest MRF technology offers improved safety to prevent complications. Appropriate patient selection, setting, and protocols are mandatory to achieve optimal clinical outcomes. The Trial Registration Number: TCTR20 210326002.

Introduction The Coronavirus disease 2019 (COVID-19) pandemic has greatly affected medical practices worldwide. Due to the transmissibility of the SARS-CoV-2 virus, the risks and benefits of conducting non-emergent and aesthetic procedures have shifted. This study primarily aimed to investigate the different factors affecting the physician’s decision to conduct dermatologic surgery procedures during the COVID-19 pandemic based on their own vaccination status. Secondly, this study also aimed to determine the level of institutional trust in the respondents’ respective governments and ministries of health. Methods This was a questionnaire-based cross-sectional study conducted from October to December 2021. The survey was electronically distributed to members of the Cyber Conference of Aesthetic Dermatology and Skin Surgery in APAC (CyAsia) and members of dermatological societies across nine countries in Asia. The survey asks the participants’ tendencies to perform procedures based on patient willingness to undergo nasal swabbing prior to the procedure, the type of procedure to be performed (cancer removal vs. filler augmentation), and the type of vaccine received by the physician (inactivated, viral vector, mRNA or protein-based). Results A total of 351 participants completed the questionnaire. Data were analyzed using a conditional logistic regression model according to the participants’ country of origin, specialty, age, level of trust in the national government, and level of trust in their respective health ministries. Tendencies to conduct dermatologic procedures were highest for doctors who received mRNA vaccines and lowest among doctors who received inactivated vaccines. Willingness of the patients to undergo pre-procedure nasal swabbing was also a significant factor in deciding to treat, whereas the type of procedure performed was a non-significant factor. Conclusions This study highlights the important factors that influence the decision to conduct dermatologic procedures during the COVID-19 pandemic. Supplementary Information The online version contains supplementary material available at 10.1007/s13555-022-00803-0.

patients. In the future, we plan to report the senior author's experience in effectively managing these complications. LimitationsLimitations include small sample size, cases obtained from a single center, and variability in documentation within the medical record.